Michel Delforge

5.1k total citations
111 papers, 1.0k citations indexed

About

Michel Delforge is a scholar working on Hematology, Oncology and Molecular Biology. According to data from OpenAlex, Michel Delforge has authored 111 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 80 papers in Hematology, 52 papers in Oncology and 24 papers in Molecular Biology. Recurrent topics in Michel Delforge's work include Multiple Myeloma Research and Treatments (56 papers), Acute Myeloid Leukemia Research (21 papers) and CAR-T cell therapy research (18 papers). Michel Delforge is often cited by papers focused on Multiple Myeloma Research and Treatments (56 papers), Acute Myeloid Leukemia Research (21 papers) and CAR-T cell therapy research (18 papers). Michel Delforge collaborates with scholars based in Belgium, United States and Spain. Michel Delforge's co-authors include Peter Vandenberghe, Meletios Α. Dimopoulos, Philippe Moreau, Gregor Verhoef, Antonio Palumbo, Nina Shah, Timothy Campbell, Albert Oriol, Pierre Zachée and Nikhil C. Munshi and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Neurology.

In The Last Decade

Michel Delforge

105 papers receiving 1.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Michel Delforge Belgium	17	716	509	486	120	113	111	1.0k
Abdul Hamid Bazarbachi United States	14	550 0.8×	479 0.9×	388 0.8×	107 0.9×	153 1.4×	30	878
Sharmilan Thanendrarajan United States	19	657 0.9×	526 1.0×	469 1.0×	124 1.0×	172 1.5×	110	1.0k
Nikolaos Kanellias Greece	21	819 1.1×	579 1.1×	710 1.5×	214 1.8×	137 1.2×	132	1.3k
Anna van Rhenen Netherlands	13	696 1.0×	408 0.8×	404 0.8×	124 1.0×	300 2.7×	39	1.2k
Wichai Chinratanalab United States	11	413 0.6×	512 1.0×	314 0.6×	99 0.8×	164 1.5×	48	1.0k
Felipe de Arriba Spain	19	1.6k 2.2×	783 1.5×	1.1k 2.2×	249 2.1×	165 1.5×	71	1.8k
Shebli Atrash United States	13	521 0.7×	454 0.9×	403 0.8×	114 0.9×	112 1.0×	119	752
Maurizio Miglino Italy	18	737 1.0×	319 0.6×	220 0.5×	260 2.2×	291 2.6×	65	1.1k
Sonia Ronconi Italy	17	836 1.2×	479 0.9×	574 1.2×	109 0.9×	112 1.0×	40	1.1k
Neil Rabin United Kingdom	16	409 0.6×	321 0.6×	396 0.8×	195 1.6×	55 0.5×	72	788

Countries citing papers authored by Michel Delforge

Since Specialization

Citations

This map shows the geographic impact of Michel Delforge's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michel Delforge with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michel Delforge more than expected).

Fields of papers citing papers by Michel Delforge

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michel Delforge. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michel Delforge. The network helps show where Michel Delforge may publish in the future.

Co-authorship network of co-authors of Michel Delforge

This figure shows the co-authorship network connecting the top 25 collaborators of Michel Delforge. A scholar is included among the top collaborators of Michel Delforge based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michel Delforge. Michel Delforge is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Morgan, Kate, Ariel Aviv, Varda Shoham, et al.. (2025). Patients and healthcare professionals’ perspectives on the implementation of shared decision making in multiple myeloma: a multinational qualitative study. BMC Medical Informatics and Decision Making. 25(1). 432–432.

Bruinink, Davine Hofste op, Vincent van der Velden, Mark van Duin, et al.. (2017). The Level of Circulating Myeloma Cells at Diagnosis Correlates with a Plasma Cell Leukemia-like Phenotype of the Corresponding Myeloma Cells in Bone Marrow. Blood. 130. 4368–4368.

Ruysscher, Dirk De, et al.. (2015). A case report of an atypical POEMS syndrome. 6(4). 156–161. 1 indexed citations

Palumbo, Antonio, Philippe Moreau, Meletios Α. Dimopoulos, et al.. (2015). OUTCOMES FOR OLDER PATIENTS WITH REFRACTORY OR RELAPSED AND REFRACTORY MULTIPLE MYELOMA TREATED WITH POMALIDOMIDE plus LOW-DOSE DEXAMETHASONE IN THE STRATUS (MM-010) TRIAL, A SINGLE-ARM, PHASE 3B STUDY. Haematologica. 100. 82–83. 1 indexed citations

Yong, Kwee, Michel Delforge, Christoph Driessen, et al.. (2015). MULTIPLE MYELOMA MANAGEMENT: OUTCOMES IN REAL-WORLD PRACTICE. Haematologica. 100. 252–253. 1 indexed citations

Dimopoulos, Meletios Α., Antonio Palumbo, Paolo Corradini, et al.. (2015). THE STRATUS (MM-010) TRIAL: A SINGLE-ARM, PHASE 3B STUDY EVALUATING SAFETY AND EFFICACY OF POMALIDOMIDE plus LOW-DOSE DEXAMETHASONE IN PATIENTS WITH REFRACTORY OR RELAPSED AND REFRACTORY MULTIPLE MYELOMA. Haematologica. 100. 83–83. 1 indexed citations

Morgan, Gareth J., Antonio Palumbo, Sujith Dhanasiri, et al.. (2014). Overall survival of relapsed and refractory multiple myeloma patients after adjusting for crossover in the MM ‐003 trial for pomalidomide plus low‐dose dexamethasone. British Journal of Haematology. 168(6). 820–823. 14 indexed citations

Dierickx, Daan, Gregor Verhoef, Paul M. Clément, et al.. (2014). Characteristics, treatment and prognosis of primary central nervous system lymphoma: a single center retrospective study. Acta Clinica Belgica. 69. 1 indexed citations

Weisel, Katja, Meletios Α. Dimopoulos, Michèle Cavo, et al.. (2014). Pomalidomide + Low-Dose Dexamethasone in Patients with Refractory or Relapsed and Refractory Multiple Myeloma and Renal Impairment: Analysis of Patients from the Phase 3b Stratus Trial (MM-010). Blood. 124(21). 4755–4755. 9 indexed citations

10.

Palumbo, Antonio, Meletios Α. Dimopoulos, Michel Delforge, et al.. (2010). A phase 3 study to determine the efficacy and safety oflenalidomide combined with melphalan and prednisone in patients= 65 years with newly diagnosed multiple myeloma (NDMM). 95. 234–235. 12 indexed citations

11.

Meers, Stef, Peter Vandenberghe, Marc Boogaerts, et al.. (2008). 5-aza-2 '-deoxycytidine can induce differentiation of clonal abnormal progenitor cells from patients with myelodysplastic syndromes without induction of apoptosis. Haematologica. 93. 91–91. 4 indexed citations

12.

Palumbo, Antonio, Rudolf Schlag, Nuriet K. Khuageva, et al.. (2008). Prolonged therapy with bortezomib plus melphalan-prednisone (vmp) results in improved quality and duration of response in the phase iii vista study in previously untreated multiple myeloma (mm). 93. 83–83. 7 indexed citations

13.

Brand, R., Anja van Biezen, Renée M. Y. Barge, et al.. (2003). Allogeneic stem cell transplantation with matched related and unrelated donors for patients with refractory anemia: T-cell depletion and reduced intensity regimens are associated with increased relapse risk. Blood. 102(11). 1 indexed citations

14.

Witte, T de, R. Brand, Anja van Biezen, et al.. (2003). Autologous peripheral stem cell transplantation of patients with high-risk MDS or AML following MDS results in equivalent outcome when compared to autologous bone marrow transplantation. Bone Marrow Transplantation. 31. 1 indexed citations

15.

Ossenkoppele, G. J., Wilfried J. Graveland, Pieter Sonneveld, et al.. (2002). Final analysis of a randomized study on the value of fludarabine in addition to ARA-C and G-CSF in the treatment of patients with high risk myelodysplastic syndromes and elderly AML. Blood. 100(11). 2 indexed citations

16.

Ossenkoppele, GJ, Bronno van der Holt, Pieter Sonneveld, et al.. (2001). A randomized study on the value of Fludarabine in addition to ARA-C and G-CSF in the treatment of patients with high risk myelodysplastic syndromes and elderly AML. A report from the Dutch-Belgian hemato-oncology cooperative group (HOVON). Blood. 98(11). 2 indexed citations

17.

Witte, T de, Stefan Suciu, Michel Delforge, et al.. (2001). Cytogenetic risk group and cytogenetic response predict outcome of patients with poor-risk mds and secondary aml treated with intensive chemotherapy and stem cell transplantation in a joint study (CRIANT) of the EORTC, EBMT, SAKK, HOVON and GIMEMA leukemia groups. Blood. 98(11). 1 indexed citations

18.

Witte, T de, R. Brand, Anja van Biezen, et al.. (2001). Peripheral stem cells are the preferred source of stem cells for autologous stem cell transplantation (ASCT) of young patients with MDS or AML following MDS: An analysis of the chronic leukaemia working party of the European blood and marrow transplantation group (EBMT). Blood. 98(11). 4 indexed citations

19.

Dijk, Johannes van, Manuel Aivado, Michel Delforge, et al.. (2001). Analysis of clonality by HUMARA PCR in high risk MDS patients before and after intensive anti-leukemic treatment. Blood. 98(11). 1 indexed citations

20.

Delforge, Michel, et al.. (2000). Reduced expression of alpha 5 beta 1 integrins on CD34(+) marrow progenitors of MDS patients with high levels of apoptosis. Blood. 96(11). 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact